Specific Biologics, a Toronto, Canada-based early-stage biotechnology company, received an additional investment from Lumira Ventures and adMare BioInnovations.
The amount of the deal was not disclosed. In conjunction with the investment, Specific Biologics has appointed Steven Kanner, PhD, as an Independent Director. Dr. Kanner joins Brent Stead, PhD, MBA, as well as seasoned company builders Daniel Hétu, MD, MBA of Lumira Ventures, Nikhil Thatte, B.Eng of Lumira Ventures and Frédéric Lemaître Auger, MSc, PhD, MBA of adMare BioInnovations.
The company intends to use the funds to advance the preclinical development of therapeutics based on its proprietary Dualase® platform gene editors in liver, ocular and CNS disorders and continue the development of Dualase gene editors for Cystic Fibrosis with preclinical studies supported by the Cystic Fibrosis Foundation.
Led by CEO Brent Stead, PhD, MBA, Specific Biologics is developing its proprietary two-site Dualase® platform gene editors to build a pipeline of treatments for serious genetic diseases. Dualase’s two-site mechanism of action enables efficient and precise disruption and repair in therapeutic areas that are not easily addressed with existing gene editors.
Specific has demonstrated the benefit of this two-site mechanism in externally validated studies in disease-relevant models at a broad and diverse set of genetic mutations where Dualase uniquely addresses the mutation or has a differentiated advantage.
FinSMEs
16/10/2023